You are here

CHEMOTHERAPY DRUG ANALYZER

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA094457-01
Agency Tracking Number: CA094457
Amount: $99,961.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
REAL-TIME ANALYZERS 87 CHURCH ST
EAST HARTFORD, CT 06108
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 STUART FARQUHARSON
 (860) 528-9806
 STU@REAL-TIME-ANALYZERS.COM
Business Contact
 STUART FARQUHARSON
Phone: (860) 528-9806
Email: FARQU@AFRINC.COM
Research Institution
N/A
Abstract

The overall objective of the proposed program is to develop a bed-side analyzer capable of providing rapid identification and quantification of chemotherapy drugs and metabolites in serum and urine. The analyzer would allow optimizing effectiveness and
minimizing adverse side-effects associated with chemotherapy drugs administered during cancer treatment. The analyzer will use capillary electrophoresis to separate drugs from body fluids with minimal sample preparation, Raman
spectroscopy to identify the drugs, and surface-enhanced Raman spectroscopy (SERS) to increase sensitivity and allow quantification at physiologic
concentrations. The Phase I program will demonstrate feasibility through three
tasks with the following objectives: 1) develop the SER active sol-gel
chemistry for selective adsorption of polar or nonpolar and positive or
negative chemical groups; 2) test and refine chemical selectivity and SER
activity of the sol-gels using p-aminobenzoic acid, phenyl acetylene, benzoic
acid, aniline, camptothecin, carboplatin, cyclophosphamide, 5-fluorouracil, and
8-oxyguanine; and 3) test ability to selectively measure these chemicals and
drugs with detection limits of <50 ng/ml and 5 ng/ml in simulated serum and
urine samples, respectively. In Phase II a prototype bed-side analyzer will be
engineered and head-to-head comparisons to existing technology will be
performed

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government